Investment Rating - The report maintains a "Buy" rating for Giant Biogene Holding (2367.HK) with a 12-month price target of HK$71.00, indicating a potential upside of 25.1% from the current price of HK$56.75 [1][15][34]. Core Insights - Giant Biogene is expected to achieve a year-on-year sales growth of 23% to RMB3,116 million and a net income growth of 20% to RMB1,183 million for 1H25, with an adjusted net profit of RMB1,205 million, reflecting a 17% increase year-on-year when excluding ESOP expenses [1][18][20]. - The company is positioned to benefit from the upcycle in China's functional skincare market, leveraging its strengths in recombinant collagen and expanding its online presence through key brands Comfy and Collgene [37][38]. Summary by Sections Financial Performance - Revenue forecasts for 2025-2027 have been revised upwards by 0-2% due to more resilient margins and faster sales recovery than previously estimated [15][34]. - The expected gross profit margin (GPM), operating profit margin (OPM), and net profit margin (NPM) for 1H25 are projected at 81.7%, 41.3%, and 38.0% respectively [25][26]. Market Trends - Online gross merchandise volume (GMV) has shown a recovery trajectory, increasing by 58% year-on-year on Douyin as of July, significantly outperforming peers [2][31]. - The report highlights a minimal contribution from KOL livestreaming, which accounted for approximately 10% of sales on Douyin in July, down from 20% in the same period last year [2]. Brand Performance - The Comfy brand is anticipated to deliver 21% growth in online sales and 16% growth in offline sales for 1H25, while the Collgene brand is expected to grow by 70% online but decline by 5% offline [23][28]. - The report emphasizes the company's strategies to revitalize brand momentum, particularly in preparation for the Double 11 shopping festival [2].

Investment Rating - The report maintains a Neutral rating for Haidilao International Holding with a 12-month price target of HK$15.30, implying an upside potential of 8.4% from the current price of HK$14.12 [1][2][26]. Core Insights - The earnings forecasts for Haidilao have been revised down by 13%-16% for 2025-27, primarily due to lower-than-expected performance in 1H25, slower store expansion, and the company's strategy to offer better value to customers [2][23][27]. - The company is expected to experience a revenue decline of 4% year-on-year in 1H25, driven by weaker table turn performance and a decrease in party size, although a slight improvement in average selling price (ASP) may provide some offset [20][21]. - Despite the challenges in 1H25, the second half is anticipated to show a recovery in same-store sales growth (SSSG) due to an easier comparison base, which could lead to slight positive growth in average sales per store [2][22]. Summary by Sections Earnings Forecasts - The report projects a revenue of Rmb20.6 billion for 1H25, reflecting a 4% decline year-on-year, with restaurant revenue expected to drop by 6% [20][21]. - For 2025, total revenue is estimated at Rmb43.09 billion, down from the previous estimate of Rmb44.62 billion, marking a 3.4% reduction [25]. Margin Analysis - The gross profit margin (GPM) is expected to contract to 60.7% in 1H25, down from 61.0% in 1H24, due to increased food cost ratios and operating deleverage [1][21]. - Operating profit margin (OPM) is projected to decrease by 0.8 percentage points year-on-year to 11.8% [21]. Store Expansion and Performance - The company is expected to close 8 net stores in 1H25, indicating a cautious approach to expansion amid fluid consumption trends [20]. - The total store count for Haidilao is projected to decrease by 30 stores in 2025, with a total of 1,415 stores expected [25]. Valuation Metrics - The report provides a valuation of 16X for the 2025 estimated price-to-earnings (P/E) ratio, with a projected dividend yield of 6% [2][13]. - The adjusted EBITDA for 2025 is forecasted at Rmb8,063.4 million, reflecting a decline from previous estimates [25]. Key Focus Areas for Investors - Investors are advised to monitor the trends in table turn performance, store expansion plans, margin outlook, and the impact of delivery subsidies on overall performance [22][23].

Investment Rating - The report maintains a "Buy" rating for JD Health International (6618.HK) [1][21]. Core Insights - JD Health's share price has increased by 60% year-to-date, outperforming the Hang Seng Index and peers [1]. - The company is focusing on on-demand initiatives, market share growth, and disciplined capital allocation as key areas of interest [1][20]. - JD Health is expected to achieve 18% year-on-year topline growth for 2Q25, with a stable profit margin despite increased investments [20][24]. Summary by Sections On-Demand Initiatives - JD Health is rapidly expanding its preposition warehouses in tier-1 cities, targeting around 200 warehouses by the end of FY25 [2]. - The competition in the on-demand space remains disciplined, with JD Health focusing on quality and variety rather than aggressive sales volume increases [2][19]. - Higher investments and promotions are anticipated in the second half of FY25 to drive online-to-offline (O2O) growth [2][28]. Market Share and Growth - JD Health is gaining market share in the online drug category, with strong user engagement expected to drive traffic and transactions [3][19]. - The competitive landscape is evolving, with ongoing debates about B2C versus O2O competition in the pharmaceutical sector [3][19]. - The company is projected to outperform peers, with a diverging sales growth trend compared to competitors [21][27]. Financial Projections - Revenue forecasts for JD Health are set at RMB 58,159.9 million for FY24, increasing to RMB 88,638.8 million by FY27 [6][17]. - EBITDA is expected to grow significantly, with projections of RMB 1,684.2 million for FY24 and RMB 3,601.3 million for FY27 [6][17]. - The report anticipates a net profit of RMB 4,161.8 million for FY24, increasing to RMB 6,608.1 million by FY27 [17][39]. Capital Allocation - JD Health has over RMB 50 billion in net cash, representing approximately 50% of its market capitalization, which will be a focus in upcoming results [20][21]. - The company is expected to maintain a disciplined spending pattern while exploring opportunities for investments and shareholder returns [21][39].

Investment Rating - The report maintains a "Buy" rating for Laopu Gold (6181.HK) with a target price of HK$1,090, based on a 25x target P/E for 2027E [9][27]. Core Insights - Laopu Gold is expected to report significant growth in sales and net profit for 1H25, with forecasts of 268% and 284% year-over-year growth, respectively, reaching RMB12,963 million in sales and RMB2,259 million in net profit [1][17]. - The company is focusing on several key strategies for 2H25, including gross profit margin (GPM) management, store optimization, high ticket size SKU launches, and overseas expansion, particularly in Singapore [2][8]. - The GPM is projected to contract by 2.1 percentage points year-over-year to 39.3% due to raw material cost pressures, despite a price hike of less than 10% implemented earlier [8][24]. Summary by Sections Financial Performance - Laopu Gold's revenue is forecasted to grow from RMB8,505.6 million in 2024 to RMB27,121.8 million in 2025, with EBITDA expected to increase from RMB2,123.6 million to RMB6,603.5 million over the same period [4][28]. - The adjusted net profit for 1H25 is expected to be RMB2,409 million, reflecting a 294% increase year-over-year when excluding ESOP expenses [1][17]. Market Position and Strategy - The company is experiencing strong sales per store, with an average of RMB300 million, and a same-store sales growth (SSSG) of 150% [8]. - Laopu Gold plans to expand its store network, with new openings in key locations such as Shanghai and Singapore, which are anticipated to support additional SSSG [2][8]. Valuation Metrics - The report outlines various valuation metrics, including a P/E ratio of 14.1 for 2024, increasing to 29.6 for 2025, and a projected dividend yield of 5.2% for 2024 [4][9]. - The company’s financial returns are highlighted by a CROCI of 50.1% for 2024, indicating strong profitability relative to capital employed [4][9]. Growth Projections - The report anticipates continued growth in net income, projecting RMB4,733 million for 2025 and RMB6,623 million for 2026, with year-over-year growth rates of 221% and 40%, respectively [29]. - The expected margins for 1H25 include a gross profit margin of 39.3%, operating profit margin of 23.6%, and net profit margin of 17.4% [17][24].

Investment Rating - The report initiates coverage of Hengrui Pharma's H-shares and resumes coverage of A-shares, both with an Overweight (OW) rating, with H-shares being the preferred stock [1][43]. Core Insights - Hengrui Pharma is positioned to benefit from an improving domestic policy environment and accelerated globalization, which has not yet been fully reflected in the market [1]. - The company is recognized for its extensive and balanced product portfolio, with a strong pipeline across various therapeutic areas, including oncology, metabolic and cardiovascular diseases, immunology, and respiratory diseases [3][12]. - Hengrui is expected to receive approvals for 5, 5, and 11 new drugs in 2025, 2026, and 2027, respectively, totaling 47 NDA/BLA approvals from 2025 to 2027 [3][10]. Summary by Sections Market Potential - The global pharmaceutical market is valued at $1.47 trillion, approximately 6.6 times the size of the Chinese domestic market, with a projected CAGR of 5.7% from 2023 to 2028 [3][32]. - Hengrui has completed 14 licensing deals since 2018, with a total transaction value of $15 billion, indicating strong interest from global biopharma companies in assets from China [3][32]. Financial Projections - The target price for H-shares is HK$78, representing a 45% upside, while the target price for A-shares is RMB 71, representing a 37% upside [7][43]. - Revenue and net profit are projected to grow at CAGRs of 18% and 24%, respectively, from 2024 to 2027 [4][37]. - Innovative drug sales are expected to grow at a CAGR of 34% from 2024 to 2027, contributing to 74% of total drug sales by 2027 [38][40]. Product Pipeline - Hengrui has developed a comprehensive pipeline of innovative drugs, with a focus on key disease areas and a one-stop solution for various subtypes and treatment needs [19][21]. - The company is advancing multiple GLP-1 products targeting the $100 billion global diabetes market, with competitive clinical data supporting their efficacy [19][20]. Valuation Analysis - The DCF valuation method yields a target price of HK$78 for H-shares and RMB 71 for A-shares, with a reasonable premium due to Hengrui's leading position and growth potential [4][43]. - The SOTP analysis indicates that the contribution of globalization opportunities to total value is still conservative, accounting for only 13% of the total estimated value [4][43].

Investment Rating - The report maintains a "Buy" rating for CATL A/H shares with a 12-month price target of Rmb 323.00 for A-shares and HK$ 411.00 for H-shares, indicating an upside of 19.3% and 6.8% respectively [8][15]. Core Insights - The report highlights three key focuses for CATL: unit gross profit (GP) expansion, upward trend in capital expenditures (CAPEX), and progress in the US market which may enhance the total addressable market (TAM) [15][16]. Summary by Sections Earnings Preview - CATL is expected to report revenue of Rmb 104.7 billion and net profit of Rmb 15.6 billion in 2Q25, with unit GP anticipated to increase to Rmb 150/kWh from Rmb 147/kWh in 1Q25, driven by strong overseas shipments [1][41]. Unit GP Expansion - The blended battery unit GP is projected to expand due to improved product mix, with overseas EV sales in Europe showing a 28% year-over-year growth in the first five months of 2025 [1][19]. CATL is estimated to account for about 70% of Europe's battery imports from China [1][20]. CAPEX Trends - The report revises up CAPEX forecasts for 2025-2027 by 25%-5%, expecting CATL's relative CAPEX share to rise from approximately 13% in 2024 to around 24% in 2025, which is expected to drive market share gains [16][30]. US Market Progress - Recent developments regarding Ford's Michigan LFP battery factory, which utilizes CATL's technology, suggest improved market access for CATL in the US, potentially increasing its TAM [16][19]. Financial Projections - Revenue projections for CATL are set at Rmb 362 billion for 2024, Rmb 436 billion for 2025, and Rmb 532 billion for 2026, with EBITDA expected to grow significantly over the same period [3][13]. EPS is forecasted to increase from Rmb 11.58 in 2024 to Rmb 22.45 by 2027 [3][13]. Market Position - CATL's market capitalization is noted at Rmb 1.2 trillion, with a strong enterprise value of Rmb 972.5 billion, indicating robust financial health and market positioning within the battery industry [3][5].

Investment Rating - The report does not explicitly provide an investment rating for Time Interconnect (1729.HK) Core Insights - Time Interconnect is expected to experience revenue growth in 2025 driven by rising AI demand, production site diversification, and exposure to various end markets [1][8] - The company reported revenues of HK$7.4 billion in 2024, with a gross margin of 14.6% [3] - The revenue from server ODM business reached HK$3.2 billion in 2024, accounting for 43% of total revenue [7] Summary by Sections Industry Overview - Time Interconnect specializes in customized copper and optical fiber cables, as well as servers ODM, with production sites in mainland China, Japan, and Mexico [3] - Key applications include telecommunications, data centers, industrial equipment, medical equipment, and automotive wiring harnesses [3] Growth Drivers - AI demand is driving the adoption of high-speed cables, with a reported 208% year-over-year growth in high-speed cable revenues in 2024 [4] - 42% of cable assembly revenues were derived from data center clients in 2024, indicating strong demand from this sector [4] Business Outlook - Management is optimistic about revenue growth in 2025, supported by the expansion of the Mexican production site and increasing capex spending from Chinese CSP clients [8] - The planned acquisition of Leoni AG is expected to diversify the business into automotive cables and wiring harnesses [8]

Investment Rating - The report maintains a Neutral rating for Hua Hong, with a 12-month target price of HK$40.9, indicating a relatively lower upside potential from the current price of HK$35.65, which translates to an upside of 14.7% [1][12]. Core Insights - Hua Hong's management is optimistic about operations, reporting that utilization (UT) rates across major fabs are at 100% or above, driven by strong demand in power discrete, microcontrollers (MCUs), and power management integrated circuits (PMICs) [1][3]. - The company has begun to implement price increases for both 8-inch and 12-inch products, anticipating that this will enhance gross margins in the upcoming quarters [2][11]. - Capacity expansion is ongoing, with plans to ramp up the second 12-inch fab to 83,000 wafers per month (wpm) and potential future capacities at 28nm and 22nm [4][11]. Pricing Outlook - The pricing strategy is set to improve, with management confident in the ability to raise prices due to solid demand, which is expected to positively impact gross margins [2][11]. Utilization Rates - Management reports full loading across its fabs, except for the new fab that is in the ramp-up phase, with a noted recovery in demand for power discrete products and sustained demand for PMICs related to AI applications [3][11]. Capacity Expansion Plans - The second 12-inch fab is being ramped up, with expectations to achieve positive gross margins once it surpasses 50,000 wpm of loading, while the first 12-inch fab is already achieving positive gross margins [4][8]. Financial Projections - Revenue projections for the next few years indicate growth, with expected revenues of $2,004 million in 2024, increasing to $3,910.5 million by 2027 [12].

Investment Ratings - PetroChina: Buy with a 12-month target price of HK$8.30/Rmb12.60, reflecting a potential upside of 21.5% [19][24] - CNOOC: Buy with a 12-month target price of HK$20.90, indicating a potential upside of 14.6% [26][29] - Sinopec: Neutral with a 12-month target price of HK$3.70/Rmb4.90, suggesting a downside of 11.7% [30][35] Core Insights - The report emphasizes a preference for free cash flow (FCF) leaders like PetroChina and CNOOC, both expected to achieve double-digit FCF yields in 2026E [2][19] - PetroChina and CNOOC are projected to achieve FCF breakeven at Brent oil prices of US$30-$40/bbl, with attractive FCF yields of approximately 11% for both companies under various oil price scenarios [21][17] - Sinopec is expected to face weak FCF due to prolonged chemical market surplus and elevated capital expenditures, leading to a Neutral rating [30][39] Summary by Sections Earnings Estimates - PetroChina's estimated net income for 2Q is projected to decline by 30% year-on-year, while Sinopec's is expected to drop by 46% [1] - CNOOC's 1H net income is estimated to decrease by 16% year-on-year [1] Valuation Comparisons - PetroChina and CNOOC are trading at discounted valuations of 3.1X-3.2X on 2026 EV/DACF compared to a global average of 5.5X [2][14] - The report highlights that both companies could maintain attractive FCF yields even at lower oil prices, with PetroChina and CNOOC achieving yields of approximately 10% and 9% respectively at US$60/bbl [2][18] Price Sensitivity Analysis - For PetroChina, total EBITDA is projected to range from Rmb351.6 million at US$50/bbl to Rmb542.5 million at US$90/bbl [20] - CNOOC's EBITDA is expected to range from Rmb176.2 million at US$50/bbl to Rmb308.0 million at US$90/bbl [28] Market Dynamics - Recent geopolitical events have supported oil prices, leading to low domestic oil product inventories and robust refining margins despite weak demand [1][2] - The report notes that deep utilization cuts among state-owned refiners have contributed to the current market conditions [2][8]

Investment Rating - The report does not explicitly provide an investment rating for Lens Tech (300433.SZ) as it is categorized as "Not Covered" [1]. Core Insights - Management is optimistic about the demand for foldable phones, driven by differentiation, new use cases, and improved technology that enhances user experience [1][4]. - The company is diversifying its end markets beyond smartphones to include vehicle glass, AI glasses, and robotics, which supports long-term growth [1][8]. Summary by Sections Foldable Phones - Foldable phones are expected to drive significant growth, with management highlighting strong market demand and potential for increased shipments [4][7]. - The global shipment penetration rate for foldable phones is projected to rise from 1.5% in 2024 to 4.1% by 2027, excluding iPhones [2]. Vehicle Glass Expansion - Lens Tech is expanding into vehicle glasses, leveraging its experience in smartphone glass to provide high-precision and lighter-weight solutions for leading car OEMs [8]. - The company is collaborating with over 30 electric vehicle manufacturers, indicating a strategic move into the automotive sector [9]. Long-Term Outlook - Revenue growth in 2025 is anticipated to be bolstered by new smartphone model launches and the increasing trend of foldable phones [9]. - Contributions from vehicle glasses and AI/AR glasses are expected to ramp up over the long term, driven by rising popularity and affordability [9].